Cancers, Vol. 13, Pages 1196: Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer

This study suggests that rs2228528 in ERCC6 could be a potential predictor of response to FOLFIRINOX chemotherapy in patients with pancreatic cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research

Related Links:

Condition:   Pancreatic Cancer Intervention:   Other: Observation Sponsor:   RenJi Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Metastatic Pancreatic Cancer Interventions:   Drug: Donafenib;   Drug: S1 Sponsor:   Fudan University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Nature, Published online: 30 November 2021; doi:10.1038/s41586-021-04176-wAuthor Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Source: Nature AOP - Category: Research Authors: Source Type: research
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by early metastasis, late detection, and poor prognosis. Progress towards effective therapy has been slow despite significant efforts. Novel treatment approaches are desperately needed and autophagy, an evolutionary conserved process through which proteins and organelles are recycled for use as alternative energy sources, may represent one such target. Although incompletely understood, there is growing evidence suggesting that autophagy may play a role in PDAC carcinogenesis, metastasis, and survival. Early clinical trials involving autophagy in...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Glioma and pancreatic cancer are tumors with a high degree of malignancy, morbidity, and mortality. The present study explored possible molecular mechanisms and potential diagnostic and prognostic biomarker-PLPP4 of glioma and PAAD. PLPP4 is differentially elevated in glioma and PAAD tissues. Statistical analysis from TCGA demonstrated that high expression of PLPP4 significantly and positively correlated with clinicopathological features, including pathological grade and poor overall survival in glioma and PAAD patients. Following this, the methylation levels of PLPP4 also affected overall survival in clinical tissue sampl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Non-BRCA gene mutations are frequently identified in breast cancer patients with high risk factors. Family history showed a correlation with both BRCA (p = 0.005) and non-BRCA HRR gene mutation status (p = 0.036), so we strongly suggest that breast cancer patients with a BRCA-related family history receive comprehensive gene mutation testing in China, especially HRR genes, which are not only related to high risk of breast cancer, but also potentially related to poly ADP ribose polymerase inhibitor (PARPi) targeted therapy. The exact relationship of rare gene mutations to breast cancer predisposition and the pa...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Source: International Journal of General Medicine - Category: General Medicine Tags: International Journal of General Medicine Source Type: research
Conclusion: This meta-analysis showed that PEGPH20 did not improve the PFS or OS. Moreover, there was an increased incidence of serious adverse events using PEGPH20 compared to standard therapies.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
One of the most fatal forms of cancer includes cancer of the pancreas And the most rapid malignancy is observed in PDAC (pancreatic ductal adenocarcinoma). The high lethality rate is generally due to very late diagnosis and resistance to traditional chemotherapeutic agents. Desmoplastic stromal barrier results in resistance to immunotherapy. Other reasons for the high lethality rate include the absence of effective treatment and standard screening tests. Hence, there is a need for effective novel carrier systems. “A formulation, method, or device that allows the desired therapeutic substance to reach its site of acti...
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The key finding of this study was that the m6A methylation regulator gene has the main role in pancreatic tumors, and it may be used as a biomarker in the prognosis of the PAAD and for therapy purposes.PMID:34840598 | PMC:PMC8626177 | DOI:10.1155/2021/8715823
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Genetics | Pancreas | Pancreatic Cancer | Study | Ultrasound